$1.08
8.47% today
Nasdaq, Apr 03, 06:47 pm CET
ISIN
US34385P1084
Symbol
LAB

Fluidigm Corporation Stock price

$1.18
+0.17 16.83% 1M
-0.68 36.56% 6M
-0.57 32.57% YTD
-1.46 55.30% 1Y
-2.81 70.43% 3Y
-0.89 43.00% 5Y
-38.40 97.02% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.09 8.26%
ISIN
US34385P1084
Symbol
LAB
Sector

Key metrics

Market capitalization $447.20m
Enterprise Value $187.33m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.07
P/S ratio (TTM) P/S ratio 2.56
P/B ratio (TTM) P/B ratio 0.94
Revenue growth (TTM) Revenue growth 64.03%
Revenue (TTM) Revenue $174.43m
EBIT (operating result TTM) EBIT $-134.76m
Free Cash Flow (TTM) Free Cash Flow $-151.81m
Cash position $292.87m
EPS (TTM) EPS $-0.55
P/E forward negative
P/S forward 2.64
EV/Sales forward 1.11
Short interest 8.37%
Show more

Is Fluidigm Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Fluidigm Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Fluidigm Corporation forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a Fluidigm Corporation forecast:

Buy
67%
Hold
33%

Financial data from Fluidigm Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
174 174
64% 64%
100%
- Direct Costs 92 92
64% 64%
53%
82 82
64% 64%
47%
- Selling and Administrative Expenses 139 139
89% 89%
80%
- Research and Development Expense 62 62
138% 138%
35%
-118 -118
141% 141%
-68%
- Depreciation and Amortization 17 17
11% 11%
10%
EBIT (Operating Income) EBIT -135 -135
110% 110%
-77%
Net Profit -139 -139
86% 86%
-80%

In millions USD.

Don't miss a Thing! We will send you all news about Fluidigm Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fluidigm Corporation Stock News

Neutral
GlobeNewsWire
about one month ago
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that company management will participate in the following investor conferences:
Neutral
Seeking Alpha
about one month ago
Standard BioTools Inc. (NASDAQ:LAB ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Michael Egholm - President & CEO Alex Kim - Chief Operating Officer & Interim-CFO Conference Call Participants Matt Stanton - Jefferies Kyle Boucher - TD Cowen Paul Knight - KeyBanc Operator Good day, everyone, and welcome to Standard BioTools' Fourth Quarter and Full Year 202...
Neutral
GlobeNewsWire
about one month ago
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2024.

Company Profile

Fluidigm Corp. is engaged in the development, manufacture and marketing of biotechnology tools fro life sciences research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics; and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen R. Quake and Gajus V. Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.

Head office United States
CEO Michael Egholm
Employees 818
Founded 1999
Website www.standardbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today